Journal Watch · Journal for ImmunoTherapy of Cancer · 2026

Targeting <i>SPP1</i> <sup>+</sup>TAMs associated with liver metastasis reverses immunosuppression and synergizes with immunotherapy in colorectal cancer.

Targeting these populations with combination therapy effectively enhances antitumor immunity, presenting a novel translational strategy for CRC immunotherapy.

Lin Y, Chen Z, Zhao S et al.Journal for ImmunoTherapy of Cancer3 min readPharma relevance 40/100

DOI: 10.1136/jitc-2025-014128PMID: 41881501Study type: cohort / observational clinical study

TL;DR

Targeting these populations with combination therapy effectively enhances antitumor immunity, presenting a novel translational strategy for CRC immunotherapy.

Key findings

  • In preclinical models, combined regorafenib and anti-programmed cell death protein 1 therapy reduced <i>SPP1</i> <sup>+</sup>TAM infiltration and suppressed tumor growth and metastasis.<h4>Conclusion</h4>This study delineates the spatial, developmental, and metabolic heterogeneity of <i>SPP1</i> <sup>+</sup>TAMs in CRC, identifying <i>SPP1</i> <sup>+</sup>TAMs as key mediators of immunosuppression and metastasis.
  • Targeting these populations with combination therapy effectively enhances antitumor immunity, presenting a novel translational strategy for CRC immunotherapy.

What they did

This population exhibited tissue-specific differentiation trajectories and comprised two metabolic subtypes: a glycolytic <i>ATP5F1E</i> <sup>+</sup> subtype enriched in primary tumors and lymph nodes, and an oxidative phosphorylation-dominant <i>MT-CO1</i> <sup>+</sup>subtype specific to liver metastases. Spatially, <i>MT-CO1</i> <sup>+</sup> <i>SPP1</i> <sup>+</sup>TAMs localized to oxygen-rich invasive margins, while <i>ATP5F1E</i> <sup>+</sup> <i>SPP1</i> <sup>+</sup>TAMs resided in hypoxic tumor cores. Functionally, <i>SPP1</i> <sup>+</sup>TAMs drove <i>CD8</i> <sup>+</sup> T-cell exhaustion and spatial exclusion.

Full abstract (original)

Background: <h4>Background</h4>Tumor-associated macrophages (TAMs) are critically involved in colorectal cancer (CRC) progression, yet their spatial and metabolic heterogeneity across primary and metastatic microenvironments remains poorly defined, limiting therapeutic development.<h4>Methods</h4>Integrated single-cell RNA sequencing was performed on 998,204 cells from a multicenter cohort encompassing primary CRC, adjacent normal tissue, liver and lymph node metastases, and peripheral blood. Computational analyses included uniform manifold approximation and projection (UMAP) clustering, pseudotime inference, RNA velocity, and CellChat. Findings were validated using multiplex immunohistochemistry, spatial transcriptomics, and in vivo preclinical models.<h4>Results</h4>This study identified two distinct TAM populations: <i>SPP1</i> <sup>+</sup> and <i>SEPP1</i> <sup>+</sup> TAMs. <i>SPP1</i> <sup>+</sup>TAMs, associated with angiogenesis, immune evasion, and liver metastasis, were linked to poorer prognosis.

What they did: This population exhibited tissue-specific differentiation trajectories and comprised two metabolic subtypes: a glycolytic <i>ATP5F1E</i> <sup>+</sup> subtype enriched in primary tumors and lymph nodes, and an oxidative phosphorylation-dominant <i>MT-CO1</i> <sup>+</sup>subtype specific to liver metastases. Spatially, <i>MT-CO1</i> <sup>+</sup> <i>SPP1</i> <sup>+</sup>TAMs localized to oxygen-rich invasive margins, while <i>ATP5F1E</i> <sup>+</sup> <i>SPP1</i> <sup>+</sup>TAMs resided in hypoxic tumor cores. Functionally, <i>SPP1</i> <sup>+</sup>TAMs drove <i>CD8</i> <sup>+</sup> T-cell exhaustion and spatial exclusion.

Results & conclusions: In preclinical models, combined regorafenib and anti-programmed cell death protein 1 therapy reduced <i>SPP1</i> <sup>+</sup>TAM infiltration and suppressed tumor growth and metastasis.<h4>Conclusion</h4>This study delineates the spatial, developmental, and metabolic heterogeneity of <i>SPP1</i> <sup>+</sup>TAMs in CRC, identifying <i>SPP1</i> <sup>+</sup>TAMs as key mediators of immunosuppression and metastasis. Targeting these populations with combination therapy effectively enhances antitumor immunity, presenting a novel translational strategy for CRC immunotherapy.

Abstract © the authors / Journal for ImmunoTherapy of Cancer (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1136/jitc-2025-014128 · PubMed 41881501.

Why it matters for pharma & biotech

  • Relevant to Biotechnology & Methods teams tracking Journal for ImmunoTherapy of Cancer for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal for ImmunoTherapy of Cancer study find?

Targeting these populations with combination therapy effectively enhances antitumor immunity, presenting a novel translational strategy for CRC immunotherapy.

What type of study is this?

It is a cohort / observational clinical study, published in Journal for ImmunoTherapy of Cancer in 2026. This population exhibited tissue-specific differentiation trajectories and comprised two metabolic subtypes: a glycolytic <i>ATP5F1E</i> <sup>+</sup> subtype enriched in primary tumors and lymph nodes, and an oxidative phosphorylation-dominant <i>MT-CO1</i> <sup>+</sup>subtype specific to liver metastases.

Where can I read the original paper?

The original is at the publisher via DOI 10.1136/jitc-2025-014128. PubMed ID: 41881501. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Lin Y, Chen Z, Zhao S et al.. Targeting &lt;i&gt;SPP1&lt;/i&gt; &lt;sup&gt;+&lt;/sup&gt;TAMs associated with liver metastasis reverses immunosuppression and synergizes with immunotherapy in colorectal cancer.. Journal for ImmunoTherapy of Cancer (2026). DOI: 10.1136/jitc-2025-014128.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/targeting-lt-i-gt-spp1-lt-i-gt-lt-sup-gt-lt-sup-gt-tams-associated-with-014128/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides